 2. Patients with prior exposure to both a CDK46 inhibitor and a PI3KATKmTOR inhibitor are excluded from the study. Patients with prior exposure to either a PI3KAKTmTOR pathway inhibitor OR a CDK46 inhibitor but not both are allowed entry into the trial provided that adverse effects have recovered to grade 1 or less. Prior exposure to fulvestrant is permitted. 